BioNTech SE and CureVac N.V. have entered into a definitive Purchase Agreement.
Under this deal, BioNTech will acquire all shares of CureVac.
CureVac is a clinical-stage biotech company pioneering transformative medicines in oncology and infectious diseases based on mRNA technology.
This acquisition aims to boost BioNTech’s capabilities in researching, developing, manufacturing, and commercializing experimental mRNA-based cancer immunotherapies.
Each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs, valuing CureVac at about $1.25 billion.
“This marks a key milestone in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech.
The transaction is expected to close in 2025.